Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Phase 1 Completed 7 enrolled Novo Nordisk A/S

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is characterise the metabolic profile of liraglutide in plasma, urine, and faeces after a single injection of \[3H\]-liraglutide.

Timeline

Start: 2006-11
Primary completion: 2006-12
Completion: 2006-12

Publications

Results Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53. doi: 10.1124/dmd.110.034066. Epub 2010 Aug 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	0.75 mg	Subcutaneous

Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Summary

Timeline

Publications

Drugs

Indications